Skip to main content
SpringerLink
Log in

Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Patients with diabetes complicated by hypertension and microalbuminuria have elevated cardiovascular risk, and controlling blood pressure in these patients is an urgent clinical priority. The present study aimed to examine the effects of a fixed-dose combination of antihypertensives on blood pressure and microalbuminuria.

Methods

Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85–105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56).

Results

Blood pressure was significantly reduced at 1 year in both groups (−22.2/−14.6 mmHg and −19.5/−14.3 mmHg, for systolic and diastolic blood pressure respectively, P<0.001 for each), with no significant between-group difference. Reductions in microalbuminuria occurred in both groups, with mean changes at 1 year of −3.9 mg/mmol creatinine (95% CI −5.3, −2.5) for manidipine/delapril (P<0.001 vs. baseline) and −2.7 mg/mmol creatinine (95% CI −4.0, −1.3) for losartan/HCTZ (P<0.001 vs. baseline and P=0.199 between groups). Glycemia over the 1-year study was largely unaffected; the blood glucose concentration was reduced from baseline with manidipine/delapril, although not statistically significant (mean change −0.2 mmol/L, P=0.064). Both treatments were well tolerated, with discontinuation for adverse events for one (1.9%) patient in the manidipine/delapril group and two (3.6%) in the losartan/HCTZ group.

Conclusions

A fixed-dose manidipine/delapril combination represents a useful addition to the treatment options available to control hypertension complicated by diabetes and microalbuminuria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444.

    Article  PubMed  CAS  Google Scholar 

  2. Klausen KP, Parving HH, Scharling H, Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med. 2007;262:470–478.

    Article  PubMed  CAS  Google Scholar 

  3. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–360.

    PubMed  CAS  Google Scholar 

  4. Pontremoli R, Leoncini G, Viazzi F, et al. Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension. J Am Soc Nephrol. 2005;16(suppl. 1):S39–S41.

    Article  Google Scholar 

  5. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35:898–903.

    PubMed  CAS  Google Scholar 

  6. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 1999;19:1992–1997.

    PubMed  CAS  Google Scholar 

  7. Donnelly R, Yeung JM, Manning G. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens. 2003;21(suppl. 1):S7–S12.

    Google Scholar 

  8. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–232.

    Article  PubMed  Google Scholar 

  9. Ryden L, Standl E, Bartnik M, et al. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J. 2007;28:88–136.

    Article  PubMed  CAS  Google Scholar 

  10. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.

    Article  PubMed  CAS  Google Scholar 

  11. American Diabetes Association. Standards of medical care in diabetes — 2007. Diabetes Care. 2007;30(suppl. 1):S4–S41.

    Article  CAS  Google Scholar 

  12. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs. 2005;65(suppl. 2):29–39.

    Google Scholar 

  13. McCormack PL, Keating GM. Delapril/manidipine. Drugs. 2006;66:961–969.

    Article  PubMed  CAS  Google Scholar 

  14. Roca-Cusachs A, Schmieder RE, Triposkiadis F, et al. Efficacy of manidipine/delapril versus losartan/HCTZ fixed combinations in patients with hypertension and diabetes. J Hypertens. 2008;26:813–816.

    Article  PubMed  CAS  Google Scholar 

  15. Mugellini A, Dobovisek J, Planinc D, Cremonesi G, Fogari R. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther. 2004;26:1419–1426.

    Article  PubMed  CAS  Google Scholar 

  16. Mugellini A, Preti P, Zoppi A, et al. Effect of delapril-manidipine combination vs irbesartanhydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens. 2004;18:687–691.

    Article  PubMed  CAS  Google Scholar 

  17. Wright JT Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.

    Article  PubMed  CAS  Google Scholar 

  18. Fogari R, Corradi L, Zoppi A, et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens. 2007;20:1092–1096.

    Article  PubMed  CAS  Google Scholar 

  19. Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther. 2008;6:1347–1355.

    Article  PubMed  CAS  Google Scholar 

  20. Schmieder RE, Schrader J, Zidek W, et al. Low grade albuminuria and cardiovascular risk. Clin Res Cardiol. 2007;96:247–257.

    Article  PubMed  CAS  Google Scholar 

  21. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect. Circulation. 2002;106:672–678.

    Article  PubMed  CAS  Google Scholar 

  22. Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens. 2003;16:1030–1035.

    Article  PubMed  CAS  Google Scholar 

  23. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17(suppl. 2):S86–S89.

    Article  Google Scholar 

  24. Bosch J, Yusuf S, et al. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–1562.

    Article  PubMed  Google Scholar 

  25. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:1405–1412.

    Article  PubMed  CAS  Google Scholar 

  26. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882–1885.

    Article  PubMed  CAS  Google Scholar 

  27. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol. 1998;46:467–471.

    Article  PubMed  CAS  Google Scholar 

  28. Yavuz D, Koc M, Toprak A, et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst. 2003;4:197–203.

    Article  PubMed  CAS  Google Scholar 

  29. Nielsen S, Schmitz A, Knudsen RE, Dollerup J, Mogensen CE. Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension. Q J Med. 1994;87:747–754.

    CAS  Google Scholar 

  30. Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.

    Article  Google Scholar 

  31. Verdecchia P, Angeli F, Reboldi GP, Gattobigio R. New-onset diabetes in treated hypertensive patients. Curr Hypertens Rep. 2005;7:174–179.

    Article  PubMed  CAS  Google Scholar 

  32. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48:219–224.

    Article  PubMed  CAS  Google Scholar 

  33. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592–2597.

    Article  PubMed  CAS  Google Scholar 

  34. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006;98:890–894.

    Article  PubMed  CAS  Google Scholar 

  35. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–2816.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kidney and Hypertension Hospital, Federal University of São Paulo, Rua Leandro Dupret 365, São Paulo, 04025-011, Brazil

    Osvaldo Kohlmann Jr.

  2. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Alejandro Roca-Cusachs

  3. Hôpital Européen Georges Pompidou, Paris, France

    Stéphane Laurent

  4. University Hospital, Erlangen, Germany

    Roland E. Schmieder

  5. A.Ö. Krankenhaus Zell am See, Zell am See, Austria

    René R. Wenzel

  6. IRCCS Policlinico San Matteo, Pavia, Italy

    Roberto Fogari

Authors
  1. Osvaldo Kohlmann Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alejandro Roca-Cusachs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stéphane Laurent
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roland E. Schmieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. René R. Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roberto Fogari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osvaldo Kohlmann Jr..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kohlmann, O., Roca-Cusachs, A., Laurent, S. et al. Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. Adv Therapy 26, 313–324 (2009). https://doi.org/10.1007/s12325-009-0015-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0015-8

Keywords

Search

Navigation